Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Stock Information for Q32 Bio Inc.
Loading
Please wait while we load your information from QuoteMedia.